Revvity Sites Globally

Select your location.

*e-commerce not available for this region.

Australia

Austria

Belgium

Brazil *

Canada

China *

Denmark

Finland

France

Germany

Hong Kong (China) *

India *

Ireland

Italy

Japan *

Luxembourg

Mexico *

Netherlands

Norway

Philippines *

Republic of Korea *

Singapore *

Spain

Sweden

Switzerland

Thailand *

United Kingdom

United States

Whitepaper

Genetically engineered PDX models as patient avatars in preclinical evaluation of acute leukemias

Dr. Irmela Jeremias from Helmholtz Munich and her team are using gene silencing techniques to evaluate the relevance of specific tumor alterations in PDX models. The aim is to discover dependencies and drug targets in acute leukemias to improve patients’ treatment and prognosis outcomes. And they’ve done just that — read the whitepaper to learn more about the study.

For research use only. Not for use in diagnostic procedures.

To view the full content please answer a few questions

営業担当者から連絡を受けることに同意します。

お名前（名）

お名前（姓）

国

メールアドレス

会社名

郵便番号

勤務先電話番号

職種

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Download Resource

Genetically engineered PDX models as patient avatars in preclinical evaluation of acute leukemias

Download Whitepaper